Ovarian cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 6
• KRAS 6
• EGFR 3
• PTEN 2
• CTNNB1 0
• FAK 1
• MAPK 0
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• PIK3CA 3
• EZH2 1
• JNK 0
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

19 of 19+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

  NCT04190628· ABM Therapeutics Corporation· Updated 21 May 2024

  “Not related to safety concerns or lack of efficacy”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Cancer Research UK· Source

• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  NCT05503797· Fore Biotherapeutics· Source

• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

  NCT05768178· Cancer Research UK· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 13
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 57
• Machine Learning 60
• Deep Learning 36
• Cohort Studies 105
• Genome-Wide Association Study 26

• Triple-Encoding Platform for Multiplexed In Situ Profiling of Extracellular Vesicle miRNAs Enables Precision Diagnosis of Ovarian Cancer.

  ACS Nano, Oct 2026

• Molecular profiling of ovarian cancer is feasible and provides valuable therapeutic and research information to women in Aotearoa New Zealand.

  N Z Med J, Oct 2026

• Si-scRNA-seq: Enabling ambient-stable single-cell transcriptomics through spatially confined biosilicification.

  Proc Natl Acad Sci U S A, Oct 2026

• Proteomic Profiling of Endometriosis and Ovarian Endometrioid Carcinoma: A Preliminary Exploratory Study.

  Technol Cancer Res Treat, Oct 2026

• Characterizing intra- and intertumor heterogeneity in ovarian high-grade serous carcinoma subtypes using single-cell and spatial transcriptomics.

  Genome Res, Oct 2026

• Stage-Specific Rewiring of PI3K-AKT Signaling During Serous Ovarian Cancer Progression: An Integrated Transcriptomic and Network Analysis.

  Int J Mol Sci, Sept 2026

• Conserved miRNA regulators of PD-1/PD-L1 in glioblastoma and colorectal cancer.

  RNA Biol, Sept 2026

• Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity.

  J Immunother Cancer, Sept 2026

• Tumor-intrinsic IFNγ signaling and niche adaptation drive early colonization in ovarian cancer metastasis.

  Nat Commun, Sept 2026

• Deciphering the Dysregulated Pathways and Candidate Therapeutic Compounds for Primary Ovarian Cancer Using Whole Transcriptomics Data and Next Generation Knowledge Discovery Strategies.

  J Cell Mol Med, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.